Enlivex Ltd. (ENLV): Capital Expenditures
$68.0K
Year ended 2025-12-31
-79.7%
3-year compound annual growth
-41.8%
5-year compound annual growth
+3.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $68.0K | -34.0% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $103.0K | -56.4% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $236.0K | -97.1% | 2026-03-25, From 2023-01-01 |
| 2022-12-31 | $8.12M | +399.8% | 2025-04-30, From 2022-01-01 |
| 2021-12-31 | $1.62M | +59.5% | 2024-04-30, From 2021-01-01 |
| 2020-12-31 | $1.02M | +428.0% | 2023-04-10, From 2020-01-01 |
| 2019-12-31 | $193.0K | -58.1% | 2022-04-29, From 2019-01-01 |
| 2018-12-31 | $461.0K | +254.6% | 2021-04-30, From 2018-01-01 |
| 2017-12-31 | $130.0K | +622.2% | 2020-04-30, From 2017-01-01 |
| 2016-12-31 | $18.0K | -62.5% | 2020-01-23, From 2016-01-01 |
| 2015-12-31 | $48.0K | -23.8% | 2018-04-23, From 2015-01-01 |
| 2014-12-31 | $63.0K | n/m | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $2.0K | n/a | 2016-03-29, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2015-03-31, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Enlivex Ltd. (ENLV) | 2025-12-31 | $68.0K | -34.0% |
| Insmed Inc (INSM) | 2025-12-31 | $32.56M | +48.5% |
| Alkermes plc. (ALKS) | 2025-12-31 | $40.42M | +20.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $8.86M | +36.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $14.15M | -21.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.74M | +5.3% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.13M | +318.9% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $34.88M | -15.0% |
Compare ENLV, INSM, ALKS, OPK side by side · Screen every company in Pharmaceutical Preparations ↗